NEW YORK (Reuters Health) – Despite widespread use of antipsychotics in children, evidence regarding the comparative benefits and harms of first-generation (FGAs) and second-generation antipsychotics (SGAs) are “limited,” conclude the authors of a review published February 20 in Pediatrics.
The...